These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33989331)

  • 1. Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country.
    Vale DB; Silva MT; Discacciati MG; Polegatto I; Teixeira JC; Zeferino LC
    PLoS One; 2021; 16(5):e0251688. PubMed ID: 33989331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.
    van Rosmalen J; de Kok IM; van Ballegooijen M
    BJOG; 2012 May; 119(6):699-709. PubMed ID: 22251259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study.
    Jansen E; Naber SK; Aitken CA; de Koning HJ; van Ballegooijen M; de Kok I
    BJOG; 2021 Feb; 128(3):573-582. PubMed ID: 32638462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
    Kim JJ; Burger EA; Sy S; Campos NG
    J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol.
    Teixeira JC; Vale DB; Bragança JF; Campos CS; Discacciati MG; Zeferino LC
    BMC Public Health; 2020 Apr; 20(1):576. PubMed ID: 32345284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force.
    Kim JJ; Burger EA; Regan C; Sy S
    JAMA; 2018 Aug; 320(7):706-714. PubMed ID: 30140882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Computer-Assisted Cytology in a Primary hrHPV-Based Cervical Cancer Screening Programme.
    Olthof EMG; Kaljouw S; van Kemenade FJ; Uyterlinde AM; de Kok IMCM
    Cancer Med; 2024 Oct; 13(19):e70299. PubMed ID: 39400537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of cervical cancer screening strategies based on the Papanicolaou smear test in Korea.
    Ko MJ; Kim J; Kim Y; Lee YJ; Hong SR; Lee JK
    Asian Pac J Cancer Prev; 2015; 16(6):2317-22. PubMed ID: 25824757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
    Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
    Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.
    Vanni T; Luz PM; Grinsztejn B; Veloso VG; Foss A; Mesa-Frias M; Legood R
    Int J Cancer; 2012 Jul; 131(2):E96-104. PubMed ID: 21964797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of p16/Ki-67 Dual-Stained Cytology Reflex Following Co-testing with hrHPV Genotyping for Cervical Cancer Screening.
    Harper DM; Anderson RJ; Baker E; Yu TM
    Cancer Prev Res (Phila); 2023 Jul; 16(7):393-404. PubMed ID: 37210751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.
    Chow IH; Tang CH; You SL; Liao CH; Chu TY; Chen CJ; Chen CA; Pwu RF
    Br J Cancer; 2010 Dec; 103(12):1773-82. PubMed ID: 21102588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of strategies for managing women with equivocal cytological results in Brazil.
    Vanni T; Legood R; Franco EL; Villa LL; Luz PM; Schwartsmann G
    Int J Cancer; 2011 Aug; 129(3):671-9. PubMed ID: 20886598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Evaluation of Cervical Cancer Screening by HPV DNA, VIA, and Pap smear Methods in Indonesia.
    Hafidz F; Icanervilia AV; Rizal MF; Listiani P; Setyaningsih H; Sasanti ML; Ekawati FM; Atthobari JA; Utami TW; Trirahmanto A; Tjokroprawiro BA; Harsono AB; Masytoh LS; Haryani W; Subekti Y; Nadjib M
    Asian Pac J Cancer Prev; 2024 Sep; 25(9):3015-3022. PubMed ID: 39342578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.
    Burger EA; Ortendahl JD; Sy S; Kristiansen IS; Kim JJ
    Br J Cancer; 2012 Apr; 106(9):1571-8. PubMed ID: 22441643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of 21 alternative cervical cancer screening strategies.
    Chuck A
    Value Health; 2010; 13(2):169-79. PubMed ID: 19804436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model.
    de Kok IM; van Rosmalen J; Dillner J; Arbyn M; Sasieni P; Iftner T; van Ballegooijen M
    BMJ; 2012 Mar; 344():e670. PubMed ID: 22391612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The health and economic effects of HPV DNA screening in The Netherlands.
    Berkhof J; Coupé VM; Bogaards JA; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ
    Int J Cancer; 2010 Nov; 127(9):2147-58. PubMed ID: 20112339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
    Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
    Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years.
    Jin XW; Lipold L; Foucher J; Sikon A; Brainard J; Belinson J; Schramm S; Nottingham K; Hu B; Rothberg MB
    J Gen Intern Med; 2016 Nov; 31(11):1338-1344. PubMed ID: 27418345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.